### THERAPEUTIC DISCOVERY

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1841</td>
<td>First Evidence of Sphingosine 1-Phosphate Lyase Protein Expression and Activity Downregulation in Human Neoplasm: Implication for Resistance to Therapeutics in Prostate Cancer</td>
<td>Leyre Brizuela, Isabelle Ader, Catherine Mazeronnes, Magalie Bocquet, Bernard Malavaud, and Olivier Cuvillier</td>
</tr>
<tr>
<td>1852</td>
<td>Induction of the Transcriptional Repressor ZBTB4 in Prostate Cancer Cells by Drug-Induced Targeting of MicroRNA-17-92/106b-25 Clusters</td>
<td>KyoungHyun Kim, Gayathri Chadalapaka, Satya S. Pathi, Un-Ho Jin, Ju-Seog Lee, Yun-Yong Park, Sung-Gook Cho, Sudhakar Chintharlapalli, and Stephen Safe</td>
</tr>
<tr>
<td>1873</td>
<td>Oxidative Stress Induced by Curcumin Promotes the Death of Cutaneous T-cell Lymphoma (HuT-78) by Disrupting the Function of Several Molecular Targets</td>
<td>Mohammad Aslam Khan, Satindra Gahlot, and Sekhar Majumdar</td>
</tr>
<tr>
<td>1884</td>
<td>Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the βGBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo</td>
<td>Livio Mallucci, Dong-yun Shi, Derek Davies, Peter Jordan, Alastair Nicol, Lavinia Lotti, Renato Mariani-Costantini, Fabio Verginelli, Valerie Wells, and Daniel Zicha</td>
</tr>
</tbody>
</table>

### PRECLINICAL DEVELOPMENT

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1905</td>
<td>Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-kB Pathways</td>
<td>Xinqui Wu, Jingjing Li, Meijun Zhu, Jonathan A. Fletcher, and F. Stephen Hodi</td>
</tr>
<tr>
<td>1915</td>
<td>Targeted Expression of BikDD Eliminates Breast Cancer with Virtually No Toxicity in Noninvasive Imaging Models</td>
<td>Xinhua Xie, Laisheng Li, Xiangsheng Xiao, Jiaoli Guo, Yanan Kong, Mingqing Wu, Wanli Liu, Guoquan Gao, Jennifer L. Hsu, Weidong Wei, Mien-Chie Hung, and Xiaoming Xie</td>
</tr>
<tr>
<td>1925</td>
<td>ATP Citrate Lyase Knockdown Induces Growth Arrest and Apoptosis through Different Cell- and Environment-Dependent Mechanisms</td>
<td>Nousheen Zaidi, Ines Royaux, Johannes V. Swinnen, and Karine Smans</td>
</tr>
</tbody>
</table>

---

Trans,trans,trans-\([\text{Pt}^4(\text{N}_3)_2(\text{OH}_2)(\text{py})(\text{NH}_3)]\): A Light-Activated Antitumor Platinum Complex That Kills Human Cancer Cells by an Apoptosis-Independent Mechanism


Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-kB Pathways

Xinqui Wu, Jingjing Li, Meijun Zhu, Jonathan A. Fletcher, and F. Stephen Hodi

Targeted Expression of BikDD Eliminates Breast Cancer with Virtually No Toxicity in Noninvasive Imaging Models

Xinhua Xie, Laisheng Li, Xiangsheng Xiao, Jiaoli Guo, Yanan Kong, Mingqing Wu, Wanli Liu, Guoquan Gao, Jennifer L. Hsu, Weidong Wei, Mien-Chie Hung, and Xiaoming Xie

ATP Citrate Lyase Knockdown Induces Growth Arrest and Apoptosis through Different Cell- and Environment-Dependent Mechanisms

Nousheen Zaidi, Ines Royaux, Johannes V. Swinnen, and Karine Smans
1948 Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models Caroline C. Clark, Jeffrey N. Weitzel, and Timothy R. O’Connor

1959 TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells Daniel P. Fitzgerald, David L. Emerson, Yongzhen Qian, Talha Anwar, David J. Liewehr, Seth M. Steinberg, Sandra Silberman, Diane Palmieri, and Patricia S. Steeg

1968 Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target Yongli Guo, Fadzai Chinyengetere, Andrey V. Dolinko, Alexandra Lopez-Aguirau, Yun Lu, Fabrizio Galimberti, Tian Ma, Qing Feng, David Sekula, Sarah J. Freemantle, Angeline S. Andrew, Vincent Memoli, and Ethan Dmitrovsky


1988 YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels Bhavna Kumar, Arti Yadav, James C. Lang, Michael J. Cipolla, Alessandra C. Schmitt, Nicole Arradaza, Theodoros N. Teknos, and Pawan Kumar


2009 The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2 Rupashree Sen, Karthika Natarajan, Jasjeet Bhullar, Suneeet Shukla, Hong-Bin Fang, Ling Cai, Zhe-Sheng Chen, Suresh V. Ambudkar, and Maria R. Baer

2014 MLN0905, a Small-Molecule PLK1 Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma Judy Quju Shi, Kerri Lasky, Vasiliki Shinde, Bradley Stringer, Mark G. Qian, Debra Liao, Ray Liu, Denise Driscoll, Michelle Tighe-Nestor, Benjamin S. Amidon, Youlan Rao, Matt O. Duffey, Mark G. Manfredi, Tricia J. Vos, Natalie D’Amore, and Marc L. Hyer

2016 Genetic Variation That Predicts Platinum Sensitivity Reveals the Role of miR-193b+ in Chemotherapeutic Susceptibility Dana Ziliak, Eric R. Gamazon, Bonnie LaCroix, Hae Kyung Im, Yuja Wen, and Rong Stephanie Huang

MOLECULAR MEDICINE IN PRACTICE

2062 Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials Rodrigo Dienstmann, Danila Serpico, Jordi Rodon, Cristina Saura, Teresa Macarulla, Elena Elez, Maria Alsina, Jaume Capdevila, Jose Perez-Garcia, Gessami Sanchez-Olle, Claudia Agra, Ludmilad Prudkin, Stefania Landolfi, Javier Hernandez-Losa, Ana Vivancos, and Josep Tabernero

CORRECTION

2072 Correction: Proanthocyanidins Inhibit In Vitro and In Vivo Growth of Human Non–Small Cell Lung Cancer Cells by Inhibiting the Prostaglandin E₂ and Prostaglandin E₂ Receptors

Downloaded from mct.aacrjournals.org on April 30, 2017. © 2012 American Association for Cancer Research.
ABOUT THE COVER

Immunohistochemical staining of colorectal cancer tissues using anti-FGFR2IIIc antibody. The tumor cell cytoplasm and cell membrane of adenocarcinoma showed strong immunoreactivity for FGFR2IIIc, which is a splicing isoform of FGFR2. FGFR2IIIc immunoreactivity was expressed in 27% of colorectal cancer cases, and this expression correlated with distant metastasis and poor prognosis. FGFR2IIIc-transfected colorectal cancer cells formed larger tumors in subcutaneous tissues and the cecum of immunodeficient mice. Fully human anti-FGFR2IIIc monoclonal antibody inhibited the growth and migration of colorectal cancer cells. For details, see the article by Matsuda and colleagues on page 2010.
Molecular Cancer Therapeutics

11 (9)


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/11/9

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.